Dr Grainger was the founding partner of The Cambridge Partnership.  He is a Principal Investigator in the Department of Medicine, Cambridge University, based at Addenbrooke’s Hospital, where he was a British Heart Foundation Senior Fellow from 2002 until 2007. He leads a group of a dozen scientists who specialise in the pathogenesis of inflammatory diseases and in the study of a wide range of preclinical models of human disease.  Between 2002 and 2006 he was the Director of the Translational Research Unit at Papworth Hospital NHS Trust, and sits on the management committees of a number of large clinical trials.  He has published more than 70 peer-reviewed scientific articles (including papers in leading international journals such as Science, Nature and Nature Medicine.  He is also an inventor on more than 100 patents and patent applications, and is the director of several spin-out companies, including TCPI.  His work has featured in the lay press as well as on television, and he writes popular science features for a number of publications.

Dr Mosedale is an honorary academic in the Department of Medicine, Cambridge University, where he has researched into the risk factors for coronary heart disease for more than a decade.  From 2002 to 2006, he was a Principal Investigator at the Translational Research Unit, Papworth Hospital where he led clinical trials into diagnostic products for coronary heart disease.  While trained as a biochemist, Dr Mosedale is now recognised as one of the world’s leading authorities on megavariate statistics and its applications to clinical science.  His principal expertise is in the areas of clinical trial design and analysis.  He is the chairman of the MaGiCAD management committee, and serves on various committees related to a number of other clinical studies.  His publications are featured in leading journals such as Nature Medicine, and he acted as an independent consultant before joining The Cambridge Partnership.  He is currently the CEO of Total Scientific, a new kind of contract research organisation.

Jason has almost 20 years experience in senior positions in the biotech industry. He was CEO of Funxional Therapeutics, a Cambridge-based early stage therapeutics company, from 2005 until late 2007, as well as Senior Vice President Business Development at Cambridge Antibody Technology (now MedImmune) from 1996 to 2003, and a member of its Executive Group. At CAT he completed over 20 multi-faceted transactions, generating over £90m in corporate equity and £100m in committed fees. Prior to CAT, Jason was Director of Corporate Finance at Ernst & Young LLP, in the UK and in Palo Alto, California, specializing in Life Sciences.

Raman has advised on healthcare business development and financing transactions totaling over $65 million. He founded ATPBio, a life sciences strategy and transaction consultancy, in 2002, and has built a substantial network with CEO/ CFO level in biotech and healthcare companies and with senior members of the investment community. Operational roles include Head of Corporate Development at a UK biotech, F2G Ltd. Previously he was a senior biotech analyst at a London investment bank, where he identified several successful healthcare private equity investment opportunities. Raman qualified as a medical doctor from the Queens Medical Centre, University of Nottingham, UK. He practiced clinical medicine for six years in A&E and general medicine. Raman also writes a blog on trends in biotech business, ‘ATPblog’. This is read by over 1000 senior level life science professionals including CEOs, CFOs, VCs, directors and entrepreneurs. Raman is currently acting as Chief Business Officer for Total Scientific.

In 2009 Jonathan "Jo" Davies retired from his partnership (held for more than 20 years) at the leading firm of patent attorneys, Reddie & Grose, where he founded the Cambridge office. His degree in chemistry, specialising in pharmacology, and doctorate in physiology from Oxford University laid the foundations for a highly successful career as a Chartered Patent Attorney specialising in pharmaceuticals and biotechnology. Jo was a founding member of the Biotechnology Committee for the Chartered Institute of Patent Attorneys (CIPA), and has also served on the Council and as Honorary Secretary of CIPA. Throughout his career, Jo has provided client companies with high quality strategic IP advide that has help client companies achieve successful funding of various clinical trials (for migraine, asthma and prostate cancer treatments), as well as Patent Agent Reports for Public Offerings and IP due diligence for investors.

Bob Schroff has 28 years of post-doctoral experience in university, government, biotechnology and pharmaceutical company settings in the US, where he has repeatedly demonstrated the ability to take cutting-edge technologies from the laboratory setting into clinical trials. He holds a degree in Life Sciences from the University of Missouri and a doctorate in immunology from Wake Forest University, as well as an MBA from the University of Washington. His work has resulted in 70 scientific publications, including the original publication of the AIDS syndrome in the New England Journal of Medicine while at UCLA, and the first clinical trials of monoclonal antibodies while at the National Cancer Institute. Bob was a co-founder of Funxional Therapeutics, and has been responsible for managing the non-clinical activities at FXT, including regulatory, ADME, toxicology and safety pharmacology. Bob currently leads the US operations for TCPI.

David Fox is currently an EPSRC Research Fellow in the Department of Chemistry, Warwick University, and a remarkable chemist. Having graduated from Oxford University with a degree and doctorate in chemistry, David moved to Cambridge working with Dr Stuart Warren in the Department of Chemistry, and collaborating with David Grainger on the design and synthesis of novel chemokine inhibitors. As consultant Head of Chemistry for Funxional Therapeutics, David oversaw the medicinal chemistry project that lead to the discovery of FX125L, a "pharma-grade" small molecule now in Phase II clinical trials, from an initial peptide 'hit'. David has also designed efficient scale-up routes (to Kg scale) for various pharmaceuticals, and solved a range of CMC problems for pharmaceutical company clients. He has a number of pending and granted patents in the US an elsewhere, and has published more than 40 papers in leading journals including, most recently, in JACS.